• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8+ T cell epitopes

An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8+ T cell epitopes

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2015;11(9):2322-8 .PMID: 26107442
Hit-and-run, hit-and-stay, and commensal bacteria present different peptide content when viewed from the perspective of the T cell

Hit-and-run, hit-and-stay, and commensal bacteria present different peptide content when viewed from the perspective of the T cell

by Adam | Oct 22, 2016

Vaccine. 2015 Oct 1. doi: 10.1016/j.vaccine.2015.08.099
H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance

H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance

by Adam | Oct 22, 2016

Side-stepping Regulatory T Cell-Mediated Evasion in Chronic Viral Infection to Build Better Vaccines

Side-stepping Regulatory T Cell-Mediated Evasion in Chronic Viral Infection to Build Better Vaccines

by Adam | Oct 21, 2016

Improved Personalized Vaccine and Adoptive Cell Transfer Immunotherapy Design by Immunoinformatic Analysis of Cancer Neo-epitopes

Improved Personalized Vaccine and Adoptive Cell Transfer Immunotherapy Design by Immunoinformatic Analysis of Cancer Neo-epitopes

by Adam | Oct 21, 2016

« Older Entries

Recent Posts

  • EpiVax Launches AI-Enhanced Analyses for Immunogenicity Prediction 
  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy. 

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}